Following these impressive results in type 2 diabetes, trials were carried outto assess the impact of SGLT2 inhibitors in patients with chronic kidney disease(CKD) and chronic heart failure (CHF), irrespective of their diabetic status. This evidence concerns the gene SLC5A2 and chronic kidney disease.